Untreated, Unresectable, or Metastatic Colorectal Cancer
Oncology·MeSH: Colorectal Neoplasms
Prevalence
135.0 / 100K
Incidence
36.0 / 100K/yr
5 drugs in development·2 companies·1 clinical trial
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| CAPOX | Merus N.V. (MRUS) |
Phase 1(1)
| Drug | Company |
|---|---|
| Pumitamig | Merus N.V. (MRUS) |
Phase 2/Phase 3(3)
Compare drugs
Frequently asked questions
How many drugs are in development for Untreated, Unresectable, or Metastatic Colorectal Cancer?
BioSniper tracks 5 drugs in development for Untreated, Unresectable, or Metastatic Colorectal Cancer across 2 companies.
How many clinical trials target Untreated, Unresectable, or Metastatic Colorectal Cancer?
There are 1 clinical trial targeting Untreated, Unresectable, or Metastatic Colorectal Cancer tracked by BioSniper.
What is the prevalence of Untreated, Unresectable, or Metastatic Colorectal Cancer?
The estimated prevalence of Untreated, Unresectable, or Metastatic Colorectal Cancer is approximately 135.0 per 100,000 population.
Deep-dive into Untreated, Unresectable, or Metastatic Colorectal Cancer
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis